Can an antidepressant be added for a patient with an unspecified mood disorder?

Can You Add an Antidepressant for Unspecified Mood Disorder?

You should NOT add an antidepressant for an "unspecified mood disorder" until you establish a specific diagnosis—this is critical because the risk-benefit profile differs dramatically between major depressive disorder and bipolar disorder, where antidepressants can cause harm.

Why Diagnosis Matters First

The term "mood disorder unspecified" is diagnostically insufficient for antidepressant prescribing because:

• If this is major depressive disorder (MDD): Antidepressants are first-line treatment with strong evidence 1
• If this is bipolar disorder: Antidepressants show no efficacy benefit and carry significant risks 2, 3

The Bipolar Risk Problem

Research demonstrates that adjunctive antidepressants in bipolar depression:

• Show no significant improvement in response rates (RR=1.10,95%CI: 0.98-1.23) 3
• Carry a 15.8% risk of switching to mania/hypomania in bipolar-II disorder 4
• Provide no added benefit when combined with mood stabilizers compared to mood stabilizers alone 2

The STEP-BD trial found that adding antidepressants to mood stabilizers in bipolar depression resulted in only 23.5% durable recovery versus 27.3% with mood stabilizer plus placebo—actually trending worse 2.

What You Must Do Before Prescribing

Establish whether this patient has:

1. Unipolar depression (MDD, dysthymia)

   • Any history of manic/hypomanic episodes?
   • Family history of bipolar disorder?
   • Previous antidepressant-induced mood elevation?
   • Age of onset (earlier onset suggests higher bipolar risk)

2. Bipolar disorder (I or II)

   • Even brief periods (4+ days) of elevated mood, decreased need for sleep, increased energy
   • Hypomanic episodes are frequently missed or misreported

3. Duration and severity of current symptoms

   • MDD requires ≥2 weeks of symptoms with significant functional impairment 1

If This Is Major Depressive Disorder

Select a second-generation antidepressant based on adverse effect profile, cost, and patient preference—NOT on presumed superior efficacy, as all second-generation antidepressants have equivalent effectiveness 1.

Key Implementation Points:

• Start at minimum licensed dose for at least 4 weeks before judging response 5
• Monitor within 1-2 weeks of initiation for suicidality, agitation, or behavioral changes 1
• Reassess at 6-8 weeks: If inadequate response, modify treatment (increase dose, switch, or augment) 1
• Continue 4-9 months after first response; longer if recurrent episodes 1

Adverse Effect Considerations:

• Bupropion: Lower sexual dysfunction rates
• Paroxetine: Higher sexual dysfunction rates
• All SSRIs: Increased suicide attempt risk versus placebo (requires close monitoring) 1

If This Is Bipolar Disorder

Do NOT use antidepressant monotherapy. If depression treatment is needed:

• First-line: Mood stabilizer or atypical antipsychotic alone 6, 7
• If inadequate response: Consider adding antidepressant SHORT-TERM to mood stabilizer, but evidence shows minimal benefit 2, 3
• Preferred antidepressants IF used: SSRIs or bupropion over tricyclics (lower switch risk) 6
• Monitor closely for mood switching (highest risk in first 3 months) 4

Critical Pitfall to Avoid

The most dangerous error is prescribing antidepressant monotherapy to an undiagnosed bipolar patient presenting with depression. This can precipitate:

• Acute manic/hypomanic episodes
• Rapid cycling (≥4 mood episodes/year)
• Long-term mood instability 8

Bottom line: Clarify the diagnosis before prescribing. If you cannot definitively rule out bipolar disorder, either obtain psychiatric consultation or start with a mood stabilizer rather than an antidepressant.